List of COVID-19 vaccine authorizations
List of COVID-19 Vaccine Authorizations
The List of COVID-19 Vaccine Authorizations encompasses a comprehensive overview of COVID-19 vaccines that have received authorization for emergency use or full approval by various drug regulatory authorities worldwide. The development and distribution of COVID-19 vaccines have been pivotal in the global effort to combat the COVID-19 pandemic, which was caused by the novel coronavirus SARS-CoV-2. This list details the vaccines that have played significant roles in mitigating the spread of the virus and reducing the severity of the disease.
Authorized COVID-19 Vaccines[edit]
Several COVID-19 vaccines have been authorized for use, either under emergency use authorizations (EUAs) or full approvals. These vaccines employ various technologies, including mRNA, viral vector, protein subunit, and inactivated virus technologies.
mRNA Vaccines[edit]
- Pfizer–BioNTech - This was among the first COVID-19 vaccines to receive EUA and later full approval in many countries. It utilizes mRNA technology to elicit an immune response.
- Moderna - Similar to the Pfizer–BioNTech vaccine, the Moderna vaccine uses mRNA technology and has been authorized for emergency use and full approval in numerous jurisdictions.
Viral Vector Vaccines[edit]
- Oxford–AstraZeneca - This vaccine uses a non-replicating viral vector and has been widely authorized for emergency use.
- Janssen (Johnson & Johnson) - The Janssen vaccine is a single-dose viral vector vaccine that has received EUA and approval in various countries.
Protein Subunit Vaccines[edit]
- Novavax - Employing a protein subunit platform, the Novavax vaccine has been authorized for emergency use in multiple regions.
Inactivated Vaccines[edit]
- Sinovac (CoronaVac) and Sinopharm (BBIBP-CorV) - These vaccines use inactivated virus particles to provoke an immune response and have been authorized for use in several countries, particularly in Asia and the Middle East.
Regulatory Approvals[edit]
The authorization process for COVID-19 vaccines involves rigorous evaluation of clinical trial data to ensure safety, efficacy, and quality. Regulatory bodies such as the U.S. Food and Drug Administration, the European Medicines Agency, and the World Health Organization have established frameworks for expedited review while maintaining high standards for authorization.
Global Distribution and Access[edit]
The global distribution of COVID-19 vaccines is facilitated through initiatives like COVAX, aimed at ensuring equitable access to vaccines for all countries. Despite these efforts, disparities in vaccine access continue to pose challenges in the fight against the pandemic.
Conclusion[edit]
The authorization of COVID-19 vaccines represents a monumental achievement in medical science and public health. These vaccines have been crucial in reducing the impact of the COVID-19 pandemic, saving countless lives, and paving the way for a return to normalcy. Continued vaccination efforts, along with public health measures, remain essential in controlling the spread of the virus.
-
COVID-19 RNA and DNA vaccines authorization map
-
COVID-19 adenovirus vaccines authorization map
-
COVID-19 inactivated vaccines authorization map
-
COVID-19 subunit and VLP vaccines authorization map
